Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,170,000 shares, an increase of 13.6% from the December 15th total of 1,030,000 shares. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is presently 0.9 days. Approximately 1.4% of the shares of the company are sold short.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on CLBT shares. JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Craig Hallum upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC raised their price target on Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, TD Cowen upped their price objective on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $20.57.
View Our Latest Stock Analysis on CLBT
Institutional Investors Weigh In On Cellebrite DI
Cellebrite DI Stock Down 0.9 %
CLBT opened at $22.78 on Monday. The business’s 50 day moving average is $20.76 and its 200-day moving average is $17.64. Cellebrite DI has a twelve month low of $8.23 and a twelve month high of $23.50.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm had revenue of $106.90 million for the quarter, compared to analysts’ expectations of $102.06 million. During the same period last year, the firm earned $0.09 EPS. The firm’s revenue was up 27.0% compared to the same quarter last year. As a group, equities research analysts forecast that Cellebrite DI will post 0.32 earnings per share for the current year.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
- Five stocks we like better than Cellebrite DI
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- Insider Trades May Not Tell You What You Think
- Oilfield Leader SLB: An AI Name You Need to Know
- Pros And Cons Of Monthly Dividend Stocks
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.